Management of eGFR 15 mL/min/1.73 m²

Nephrology Referral

Refer immediately to nephrology for any patient with eGFR <30 mL/min/1.73 m², as consultation at this stage reduces costs, improves quality of care, and delays dialysis, according to the American Diabetes Association 1
The Canadian Society of Nephrology recommends formal referral for GFR <30 mL/min/1.73 m² unless the finding is stable and isolated with clear diagnosis in elderly patients with limited life expectancy 2
At eGFR 15, the patient is approaching Stage 5 CKD, making preparation for renal replacement therapy urgent, as stated by the American Diabetes Association 1

Monitor creatinine, eGFR, urinary albumin excretion, and potassium twice yearly for patients with Stage 4 CKD, as recommended by the Mayo Clinic Proceedings 3
Increase monitoring frequency to quarterly or more often if there is rapid progression, new medication initiation, or change in clinical status, according to the Mayo Clinic Proceedings 3

Screen for and manage secondary hyperparathyroidism as part of CKD-mineral bone disease management, as recommended by the American Diabetes Association 1
Evaluate and correct metabolic acidosis, which commonly develops at this level of kidney function, according to the American Diabetes Association 1

Target HbA1c <7.0% for most patients, though higher targets may be appropriate for those with severe comorbidities, limited life expectancy, or high hypoglycemia risk, as recommended by the Mayo Clinic Proceedings 3
Monitor HbA1c twice yearly, increasing to quarterly if not at target or therapy changes, according to the American Diabetes Association and the Mayo Clinic Proceedings 1, 3

Canagliflozin: Maximum 100 mg daily; may continue for kidney and cardiovascular benefit until dialysis, as stated by Kidney International and Endocrine Reviews 4, 5
Metformin: Contraindicated at eGFR <30 mL/min/1.73 m²; discontinue immediately, according to Kidney International and Endocrine Reviews 4, 5
Insulin: Reduce total daily dose by 35-50% due to decreased renal clearance and reduced gluconeogenesis, as recommended by Kidney International and Endocrine Reviews 4, 5

Target systolic BP <130 mmHg and diastolic BP <80 mmHg, as recommended by the Mayo Clinic Proceedings 3
Use ACE inhibitors or ARBs as first-line agents for blood pressure control and kidney protection, according to the American Diabetes Association and the Mayo Clinic Proceedings 1, 3

Consult nephrology before administering IV fluids to patients with eGFR 15, as they are at significantly increased risk of fluid overload, as stated by Praxis Medical Insights 6
Monitor daily for signs of fluid overload when IV fluids are necessary, according to Praxis Medical Insights 6

Begin patient education about progressive nature of kidney disease and potential need for dialysis or transplantation, as recommended by the American Diabetes Association 1
Discuss options for renal replacement therapy and consider vascular access planning, according to the American Diabetes Association 1

Dialysis initiation should be considered when GFR falls below 15 mL/min/1.73 m², though certain complications of kidney failure may justify earlier initiation even before reaching this threshold, according to the American Journal of Kidney Diseases 7
It may be optimal to perform kidney transplantation or begin home dialysis before patients reach CKD stage 5 (GFR <15), as recommended by the American Journal of Kidney Diseases 8

The American College of Endocrinology, as referenced in Endocrine Reviews, recommends the following adjustments for antidiabetic medications in patients with eGFR <30 mL/min/1.73 m²: Canagliflozin maximum 100 mg daily, Sitagliptin 25 mg daily, Alogliptin 6.25 mg daily, Saxagliptin maximum dose of 2.5 mg daily if eGFR ≤45 mL/min/1.73 m², Glimepiride consider alternative if eGFR <15 mL/min/1.73 m², Glyburide avoid use, Exenatide contraindicated, Lixisenatide avoid if eGFR <15 mL/min/1.73 m², and Liraglutide, dulaglutide, and semaglutide require no dose adjustment but monitor eGFR when initiating or escalating doses 9

Certain complications justify earlier initiation of dialysis therapy, including uremic pericarditis, and uremic symptoms affecting nutrition or quality of life, as indicated by the American Journal of Kidney Diseases 7, 8

The American Journal of Kidney Diseases recommends considering kidney transplantation or home dialysis before patients reach CKD stage 5 (GFR <15) 10
Specific indications for earlier dialysis include uremic pericarditis, uremic symptoms affecting nutrition or quality of life, protein-energy malnutrition developing or persisting despite vigorous attempts to optimize intake with no apparent cause other than low nutrient intake 10

The Mayo Clinic Proceedings states that metformin is contraindicated at eGFR <30 mL/min/1.73 m² and should be discontinued immediately 11
The Mayo Clinic Proceedings recommends reducing the total daily dose of insulin by 35-50% due to decreased renal clearance and reduced gluconeogenesis, and also recommends a maximum daily dose of 100 mg for canagliflozin 11
The Mayo Clinic Proceedings suggests that dapagliflozin is not recommended for glucose lowering at eGFR <45, but may be used at a dose of 10 mg for heart failure or CKD indications if eGFR is 25-45 11
The Mayo Clinic Proceedings states that exenatide is contraindicated at CrCl <30, and lixisenatide should be avoided if eGFR <15 mL/min/1.73 m² 11